Ten years ago, in March 2007, oxo chemicals producer Oxea was established as a buyout led by private-equity firm Advent International of oxo derivatives and oxo intermediates businesses from Celanese and European Oxo.
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
Lanxess is investing some €60 million in expanding custom synthesis facilities at multi-purpose production facilities in the Central Organics Pilot Plant (ZeTO) of fine chemicals subsidiary Saltigo in Leverkusen, Germany.
